Vilaprisan

Drug Profile

Vilaprisan

Alternative Names: BAY 1002670; Bayer-sPRM; S-PRAnt; S-PRM; sPRM

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Infertility therapies; Small molecules; Sulfones
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uterine leiomyoma
  • Phase II Endometriosis

Most Recent Events

  • 20 Nov 2017 Bayer plans a phase I trial for Uterine leiomyoma in United Kingdom (PO) in December 2017 (EudraCT2017-000468-13) (NCT03342859)
  • 16 Nov 2017 Bayer initiates enrolment in a phase I trial for Uterine leiomyoma in United Kingdom (PO) (NCT03342859)
  • 17 Jul 2017 Bayer completes a phase I trial in subjects with hepatic impairment and in Healthy volunteers in Germany (NCT03092999)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top